论文部分内容阅读
目的:探究恩替卡韦在失代偿期乙型肝炎肝硬化中的治疗效果。方法:选取2011年-2014年本院收治的失代偿期乙型肝炎肝硬化患者72例,按照治疗方法的不同分为两组,每组36例,对照组给予综合保肝护肝治疗(促肝细胞生长素、还原型谷胱甘肽、甘草酸二胺等),观察组在此基础上加用恩替卡韦治疗,观察两组的治疗效果。结果:治疗后,观察组肝功能指标改善情况优于对照组,且观察组Child-Pugh评分、乙型肝炎病毒的脱氧核糖核酸(HBV-DNA)转阴情况明显优于对照组,并发症发生率低于对照组,组间比较,差异具有统计学意义(P<0.05)。结论:恩替卡韦在失代偿期乙型肝炎肝硬化患者治疗中具有较好的应用效果,能够明显改善患者的肝功能指标,降低并发症发生率。
Objective: To investigate the therapeutic effect of entecavir in decompensated hepatitis B cirrhosis. Methods: Seventy-two patients with decompensated hepatitis B cirrhosis admitted in our hospital from 2011 to 2014 were divided into two groups according to the different treatment methods, 36 cases in each group. The control group received comprehensive hepatoprotective hepatoprotective therapy Promote hepatocyte growth hormone, reduced glutathione, glycyrrhizic acid diamine, etc.) on the basis of the observation group plus entecavir treatment, the treatment effect was observed in both groups. Results: After treatment, the improvement of liver function in the observation group was better than that in the control group. The Child-Pugh score and HBV-DNA negative rate in the observation group were significantly better than those in the control group, with complications The rate was lower than the control group, the difference between the two groups was statistically significant (P <0.05). Conclusion: Entecavir has a good effect in the treatment of patients with decompensated hepatitis B cirrhosis, which can significantly improve the liver function index and reduce the incidence of complications.